TIL-) and PD-L1 expression (PD-L1 +), patients with locally recurrent pancreatic cancer treated with Stereotactic body radiation therapy (SBRT) + pembrolizumab + trametinib (SBRT + K + M) or SBRT + gemcitabine (SBRT + G) were categorized in the secondary analysis of a randomized phase II trial conducted by Zhu et al. [96]. This evidence concerns the gene CD274 and familial pancreatic carcinoma.